ADVANCES IN OBSTETRICS AND GYNECOLOGY

We have reviewed papers that discussed the effect of GnRH agonists on functional protection of the ovary during cancer treatment. Although the efficacy is over 90%, the mechanism is still not fully understood, and furthermore, recovery of the ovulation cycle and pregnancy are other matters that still need to be addressed. New methods that preserve fertility during cancer treatment must be developed. Furthermore, the effects of conventional methods for the preservation of fertility must be reviewed. [Adv Obstet Gynecol, 60 (1) : 1-5, 2008 (H20.2)]

View full abstract

Show abstractHide abstract

Pazufloxacin mesilate (PZFX), a new injectable quinolone, was safely and effectively administered in a case of multi-drug resistant pyosalpinx.
The patient was a 29-year old female with intermittent lower abdominal pain, anti-Chlamydia Ig A positive serum, and an ultrasonographic (USG) examination suggestive of marked pyosalpinx. Before administration of PZFX and Clindamycin (CLDM), Piperacillin (PIPC), Azithromycin (AZM), Minomycin (MINO), and Ceftriaxone (CTRX) were administered without improvement in clinical or laboratory findings. After PZFX administration, however, fever, WBC count, and CRP values rapidly improved. On post-treatment day 7, the pyosalpinx had resolved, and the patient's serum was negative for anti-Chlamydia Ig A. No adveres reactions or abnormal laboratory findings were observed in the case during the treatment.
The results of this case study suggest that PZFX may be used as a first-line treatment of moderate to severe female pelvic infection, especially when complicated with Chlamydia infection.[Adv Obstet Gynecol, 60 (1): 6-8, 2008 (H20.2) ]

View full abstract

Download PDF (361K)

Standard treatment procedures for recurrent epitherial ovarian cancer (EOC) are cytoreductive surgery and chemotherapy. Radiotherapy (RT) has been shown to play a role in palliative care for recurrent EOC patients. Recent studies, however, demonstrated that RT and chemotherapy (CT) showed comparable effects, particularly in the treatment of the minimal residual tumor after surgery or CT. Effects of RT were more pronounced on non-serous adenocarcinoma including clear-cell carcinoma than on serous adenocarcinoma. When RT is administered postoperatively, it is important to minimize the risk of bowel obstruction. Technical details including the radiation field, dose and duration must be carefully determined for each patient. We present here three cases of recurrent EOC who received radiotherapy after surgery. All the three cases had favorable outcomes after RT, considering the malignant/recurring nature of the tumor involved (platinum-resistant tumor, bulky residual tumor, or clear-cell carcinoma). [Adv Obstet Gynecol, 60 (1): 9-14, 2008 (H20.2)]

View full abstract

Register with J-STAGE for free!